Table 1.
The association between SLC2A3 mRNA levels and the clinicopathological parameters in 44 GC patients included in the OS analysis
| Clinicopathological parameters | SLC2A3 expression | p-value | |
|---|---|---|---|
| Low | High | ||
| Age | |||
| < 60 | 8 | 13 | p = 0.533 |
| ≥ 60 | 8 | 15 | |
| Gender | |||
| Male | 12 | 18 | p = 0.350 |
| Female | 4 | 10 | |
| pStage | |||
| I | 5 | 2 | p = 0.049 |
| II–IV | 11 | 26 | |
| pT grade | |||
| T1, 2 | 7 | 4 | p = 0.037 |
| T3, 4 | 9 | 24 | |
| pN grade | |||
| N0 | 9 | 10 | p = 0.157 |
| N1–3 | 7 | 18 | |
| pM grade | |||
| M0 | 16 | 26 | p = 0.400 |
| M1 | 0 | 2 | |
| Total | 16 | 28 | |
SLC2A3 protein expression was significantly higher in patients with pathological stage (p = 0.049) and advanced T (p = 0.037) but showed no association with age, gender, N and M grades
GC Gastric cancer, OS overall survival, TNM tumor, N lymph node, M metastasis